BRAF mutation T1796A in thyroid cancers

Details BRAF mutation T1796A in thyroid cancers BRAF mutation T1796A in thyroid cancers

2004-04-09

2008-05-27

Canella, Karen A. (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S091200, C436S064000

Reexamination Certificate

active

07378233

ABSTRACT:
The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)→adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer. Moreover, BRAF mutation reliably predicts a poor prognosis for papillary thyroid carcinomas.

REFERENCES:
patent: WO95/19448 (1995-07-01), None
patent: WO03/008583 (2003-01-01), None
Davies et al. (2002, Nature 417:949-954.
Wolf et al. (2002, Hautarzt. 53(5):332-2) (abstract only).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Kimura et al. (Apr. 1, 2003, Cancer Research 63:1454-1457).
Tyler et al. (1994, Surgery 116(6):1054-60) (abstract only).
Shaag et al (BBRC, 1997, vol. 233, pp. 637-639).
New England Biolabs On-line Catalog (1998-1999), listing for TspR1.
Weber et al., “Active Ras Induces Heterodimerization of cRraf and BRaf1”,Cancer Research, May 1, 2001, pp. 3595-3598, vol. 61.
Hogrefe R., “An Antisense Oligonucleotide Primer”,Antisense and Nucleic Acid Drug Development, 1999, Table 1 updated 2002, pp. 351-357, vol. 9.
Wilhelm et al., “Bay 43-9006: Preclinical Data”,Current Pharmaceutical Design, 2002, pp. 2255-2257, vol. 8.
Cohen et al., “BRAF Mutation in Papillary Thyroid Carcinoma”,Journal of the National Cancer Institute, Apr. 16, 2003, pp. 625-627, vol. 95, No. 8.
Namba et al., “Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers”,The Journal of Clinical Endocrinology&Metabolism, 2003, pp. 4393-4397, vol. 88(9).
Huang et al., “Gene Expression in Papillary Thyroid Carcinoma Reveals Highly Consistent Profiles”,Proceedings of the National Academy of Sciences, Dec. 18, 2001, pp. 15044-15049, vol. 98, No. 26.
Kimura et al., “High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma1”,Cancer Research, Apr. 1, 2003, pp. 1454-1457, vol. 63.
Daum et al., “The Ins and Outs of Raf Kinases”,Elsevier Science Ltd., Nov. 1994, pp. 474-480.
Davies et al., “Mutations of the BRAF Gene in Human Cancer”,Nature, Jun. 27, 2002, pp. 949-954, vol. 417.
Cripps et al., “Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study1”,Clinical Cancer Research, Jul. 2002, pp. 2188-2192, vol. 8.
Yin et al., “RNA-mediated Gene Regulation System: Now and the Future (Review)”,International Journal of Molecular Medicine, 2002, pp. 355-365, vol. 10.
Collisson et al., “Treatment of Metastatic Melanoma with an Orally Available Inhibitor of the Ras-Raf-MAPK Cascade1,2”Cancer Research, Sep. 15, 2003, pp. 5669-5673, vol. 63.
Kolch et al., “Animation of the Organisation and Function of the Ras-Raf-MEK-ERK Pathway”, Expert Reviews in Molecular Medicine: http://www.expertreviews.org, Accession Information: (02)00444- 1h.htm (shortcode: swf001 wkg); Aug. 14, 2002 (Abstract only).
Mullen et al., “Antisense Oligonucleotide Targeting of raf-1: Importance of Raf-1 mRNA Expression Levels and Raf-1-Dependent Signaling in Determining Growth Response in Ovarian Cancer”,Clinical Cancer Research, Mar. 15, 2004, pp. 2100-2108, vol. 10(6). (Abstract only).
Lee et al., “BAY-43-9006 Bayer/Onyx”,Current Opinion of Investigative Drugs, Jun. 2003, pp. 757-763, vol. 4(6). (Abstract only).
Wan et al., “Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF”,Cell, Mar. 19, 2004, pp. 855-867, vol. 116(6). (Abstract only).
Bollag et al., “Raf Pathway Inhibitors in Oncology”,Current Opinion Investigative Drugs, Dec. 2003, pp. 1436-1441, vol. 4(12). (Abstract only).

Affiliated with

Also associated with

Rating

BRAF mutation T1796A in thyroid cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BRAF mutation T1796A in thyroid cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BRAF mutation T1796A in thyroid cancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3985588